These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35897110)

  • 1. A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study.
    Speich B; Odutayo A; Peckham N; Ooms A; Stokes JR; Saccilotto R; Gryaznov D; von Niederhäusern B; Copsey B; Altman DG; Briel M; Hopewell S
    Trials; 2022 Jul; 23(1):601. PubMed ID: 35897110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, CAnada and GErmany (ASPIRE-SCAGE).
    Gryaznov D; von Niederhäusern B; Speich B; Kasenda B; Ojeda-Ruiz E; Blümle A; Schandelmaier S; Mertz D; Odutayo A; Tomonaga Y; Amstutz A; Pauli-Magnus C; Gloy V; Lohner S; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Klatte K; Ghosh N; Taji Heravi A; Wong J; Chow N; Hong P; McCord-De Iaco KA; Sricharoenchai S; Busse JW; Agarwal A; Saccilotto R; Schwenkglenks M; Moffa G; Hemkens L; Hopewell S; Von Elm E; Briel M
    BMJ Open; 2022 May; 12(5):e053417. PubMed ID: 35613804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects.
    Gryaznov D; Odutayo A; von Niederhäusern B; Speich B; Kasenda B; Ojeda-Ruiz E; Blümle A; Schandelmaier S; Mertz D; Tomonaga Y; Amstutz A; Pauli-Magnus C; Gloy V; Bischoff K; Wollmann K; Rehner L; Lohner S; Meerpohl JJ; Nordmann A; Klatte K; Ghosh N; Heravi AT; Wong J; Chow N; Hong PJ; Cord KM; Sricharoenchai S; Busse JW; Agarwal A; Saccilotto R; Schwenkglenks M; Moffa G; Hemkens LG; Hopewell S; von Elm E; Briel M
    Trials; 2020 Oct; 21(1):896. PubMed ID: 33115541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study.
    Lohner S; Gryaznov D; von Niederhäusern B; Speich B; Kasenda B; Ojeda-Ruiz E; Schandelmaier S; Mertz D; Odutayo A; Tomonaga Y; Amstutz A; Pauli-Magnus C; Gloy V; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Klatte K; Ghosh N; Heravi AT; Wong J; Chow N; Hong PJ; McCord K; Sricharoenchai S; Busse JW; Agarwal A; Saccilotto R; Schwenkglenks M; Moffa G; Hemkens LG; Hopewell S; von Elm E; Blümle A; Briel M
    J Clin Epidemiol; 2021 Nov; 139():340-349. PubMed ID: 34029678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis.
    Speich B; Gryaznov D; Busse JW; Gloy VL; Lohner S; Klatte K; Taji Heravi A; Ghosh N; Lee H; Mansouri A; Marian IR; Saccilotto R; Nury E; Kasenda B; Ojeda-Ruiz E; Schandelmaier S; Tomonaga Y; Amstutz A; Pauli-Magnus C; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Wong J; Chow N; Hong PJ; Mc Cord-De Iaco K; Sricharoenchai S; Agarwal A; Schwenkglenks M; Hemkens LG; von Elm E; Copsey B; Griessbach AN; Schönenberger C; Mertz D; Blümle A; von Niederhäusern B; Hopewell S; Odutayo A; Briel M
    PLoS Med; 2022 Apr; 19(4):e1003980. PubMed ID: 35476675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting completeness of nutrition and diet-related randomised controlled trials protocols.
    Silva FM; Amorim Adegboye AR; Curioni C; Gomes F; Collins GS; Kac G; Cook J; Ismail LC; Page MJ; Khandpur N; Lamb S; Hopewell S; Saleh S; Kirtley S; Bernardes S; Durão S; Vorland CJ; Lima J; Rebelo F; Cunha Figueiredo AC; Braga Tibaes JR; Tavares M; da Silva Fink J; Maia de Sousa T; Chester-Jones M; Bi D; Naude C; Schlussel M
    Clin Nutr; 2024 Jul; 43(7):1626-1635. PubMed ID: 38795681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not enough SPIRIT shown in the registration and reporting of orthodontic trial protocols.
    Eleftheriadi I; Ioannou T; Katechi V; Seehra J; Pandis N
    Eur J Orthod; 2023 Feb; 45(1):29-37. PubMed ID: 35639885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the reporting quality of published randomised controlled trial protocols improved since the SPIRIT statement? A methodological study.
    Tan ZW; Tan AC; Li T; Harris I; Naylor JM; Siebelt M; van Tiel J; Pinheiro M; Harris L; Chamberlain K; Adie S
    BMJ Open; 2020 Aug; 10(8):e038283. PubMed ID: 32847919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review.
    van Lent M; Rongen GA; Out HJ
    BMC Med Ethics; 2014 Dec; 15():83. PubMed ID: 25490963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.
    Clyburne-Sherin AV; Thurairajah P; Kapadia MZ; Sampson M; Chan WW; Offringa M
    Trials; 2015 Sep; 16():417. PubMed ID: 26385379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPIRIT 2013 Statement: defining standard protocol items for clinical trials.
    Chan AW; Tetzlaff JM; Altman DG; Laupacis A; Gøtzsche PC; Krle A-Jerić K; Hrobjartsson A; Mann H; Dickersin K; Berlin JA; Dore CJ; Parulekar WR; Summerskill WS; Groves T; Schulz KF; Sox HC; Rockhold FW; Rennie D; Moher D
    Rev Panam Salud Publica; 2015 Dec; 38(6):506-14. PubMed ID: 27440100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting Quality of Endoscopic Colorectal Cancer Screening Randomized Controlled Trials: Adherence to Recommendations and Interventions.
    Jaber F; Ahmed K; Hamid O; Johnson WM; Alsakarneh S; Abdalla AO; Abboud Y; Mohamed M; Dahiya DS; Umar S; Abdallah M; Bilal M; Shaukat A
    Gastro Hep Adv; 2024; 3(7):1012-1019. PubMed ID: 39309370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPIRIT 2013 statement: defining standard protocol items for clinical trials.
    Chan AW; Tetzlaff JM; Altman DG; Laupacis A; Gøtzsche PC; Krleža-Jerić K; Hróbjartsson A; Mann H; Dickersin K; Berlin JA; Doré CJ; Parulekar WR; Summerskill WS; Groves T; Schulz KF; Sox HC; Rockhold FW; Rennie D; Moher D
    Ann Intern Med; 2013 Feb; 158(3):200-7. PubMed ID: 23295957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols.
    Kyte D; Duffy H; Fletcher B; Gheorghe A; Mercieca-Bebber R; King M; Draper H; Ives J; Brundage M; Blazeby J; Calvert M
    PLoS One; 2014; 9(10):e110229. PubMed ID: 25333349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource use and costs of investigator-sponsored randomized clinical trials in Switzerland, Germany, and the United Kingdom: a metaresearch study.
    Griessbach A; Speich B; Amstutz A; Hausheer L; Covino M; Wnfried Ramirez H; Schandelmaier S; Taji Heravi A; Treweek S; Schwenkglenks M; Briel M;
    J Clin Epidemiol; 2024 Dec; 176():111536. PubMed ID: 39307405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of clinical trial protocols for pathology content using the SPIRIT-Path guidelines highlights areas for improvement.
    Robinson P; Bacon CM; Lim SJ; Shaaban AM; Brierley D; Lewis I; Harrison DJ; Kendall TJ; Robinson M
    J Pathol Clin Res; 2022 Sep; 8(5):411-421. PubMed ID: 35638866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension.
    Kendall TJ; Robinson M; Brierley DJ; Lim SJ; O'Connor DJ; Shaaban AM; Lewis I; Chan AW; Harrison DJ;
    Lancet Oncol; 2021 Oct; 22(10):e435-e445. PubMed ID: 34592193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study protocol for the development of a SPIRIT extension for trials conducted using cohorts and routinely collected data (SPIRIT-ROUTINE).
    McCarthy M; O'Keeffe L; Williamson PR; Sydes MR; Farrin A; Lugg-Widger F; Davies G; Avery K; Chan AW; Kwakkenbos L; Thombs BD; Watkins A; Hemkens LG; Gale C; Zwarenstein M; Langan SM; Thabane L; Juszczak E; Moher D; Kearney PM
    HRB Open Res; 2021; 4():82. PubMed ID: 34877471
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence, characteristics, and publication of discontinued randomized trials.
    Kasenda B; von Elm E; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl JJ; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Schandelmaier S; Xin S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Bucher HC; Guyatt GH; Briel M
    JAMA; 2014 Mar; 311(10):1045-51. PubMed ID: 24618966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation.
    Speich B; Schur N; Gryaznov D; von Niederhäusern B; Hemkens LG; Schandelmaier S; Amstutz A; Kasenda B; Pauli-Magnus C; Ojeda-Ruiz E; Tomonaga Y; McCord K; Nordmann A; von Elm E; Briel M; Schwenkglenks M;
    PLoS One; 2019; 14(1):e0210669. PubMed ID: 30633776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.